Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines
- PMID: 1764162
Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines
Abstract
Quantitative structure-activity relationship studies aimed at improving drug activity profiles require the determination of the physicochemical properties possibly involved in biological action. The lipophilic character of selected anthracyclines has been measured by means of reverse-phase high performance liquid chromatography, selecting appropriate experimental conditions. The capacity coefficients at zero percentage of the organic phase (log K0), which are retention indexes, have been used as lipophilicity descriptors in a QSAR study, involving as biological data the cytotoxicity of anthracyclines in a doxorubicin-sensitive (LoVo) and in a doxorubicin-resistant (LoVo/Dx) human cell lines. The results obtained in these in vitro models indicate that lipophilicity plays a role in anthracycline activity, influencing drug availability at the site of action.
Similar articles
-
Oxazolinodoxorubicin - a promising new anthracycline.Anticancer Res. 2012 Jul;32(7):2959-65. Anticancer Res. 2012. PMID: 22753760
-
Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.Anticancer Res. 2006 May-Jun;26(3A):2009-12. Anticancer Res. 2006. PMID: 16827137
-
In vitro studies on anthracycline haloderivatives.Drugs Exp Clin Res. 1986;12(8):657-61. Drugs Exp Clin Res. 1986. PMID: 3463498
-
Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review.Biochimie. 1984 May;66(5):333-52. doi: 10.1016/0300-9084(84)90018-x. Biochimie. 1984. PMID: 6380596 Review.
-
Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.Pharm Weekbl Sci. 1986 Apr 25;8(2):109-33. doi: 10.1007/BF02086146. Pharm Weekbl Sci. 1986. PMID: 3520474 Review.
Cited by
-
In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.Br J Cancer. 1992 May;65(5):703-7. doi: 10.1038/bjc.1992.148. Br J Cancer. 1992. PMID: 1586598 Free PMC article.
-
Uptake and intracellular distribution of idarubicin in secondary cultures of normal and neoplastic urothelium.Urol Res. 1997;25(2):125-30. doi: 10.1007/BF01037928. Urol Res. 1997. PMID: 9144880
-
Morpholinylanthracyclines: cytotoxicity and antitumor activity of differently modified derivatives.Invest New Drugs. 1996;14(2):139-46. doi: 10.1007/BF00210784. Invest New Drugs. 1996. PMID: 8913834
-
Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.Invest New Drugs. 1994;12(2):93-7. doi: 10.1007/BF00874437. Invest New Drugs. 1994. PMID: 7860237